

CI Bio-Revolution Index ETF

SUMMARY OF INVESTMENT PORTFOLIO as at September 30, 2024

Category	% of Net Assets	Category	% of Net Assets	Category	% of Net Assets
Country allocation		Sector allocation		Asset allocation	
U.S.A.	74.7	Health Care	100.5	Common Equities	100.5
Switzerland	9.0	Cash & Cash Equivalents	0.1	Cash & Cash Equivalents	0.1
Germany	3.6	Other Net Assets (Liabilities)	(0.1)	Other Net Assets (Liabilities)	(0.1)
U.K.	2.8	Foreign Currency Forward Contract(s)	(0.5)	Foreign Currency Forward Contract(s)	(0.5)
China	2.5				
Netherlands	2.4				
South Korea	2.4				
Denmark	1.7				
Ireland	1.4				
Cash & Cash Equivalents	0.1				
Other Net Assets (Liabilities)	(0.1)				
Foreign Currency Forward Contract(s)	(0.5)				

The summary of investment portfolio may change due to ongoing portfolio transactions of the Fund and updates are available on a quarterly basis.

The prospectus and other information about the fund are available on the internet at www.ci.com.



CI Bio-Revolution Index ETF

SUMMARY OF INVESTMENT PORTFOLIO as at September 30, 2024 (cont'd)

Top 25 Holdings	% of Net Assets
BioNTech SE, ADR	3.6
Bristol-Myers Squibb Co.	3.2
Illumina Inc.	3.0
AbbVie Inc.	2.9
Vertex Pharmaceuticals Inc.	2.9
Novartis AG, Registered	2.7
Exact Sciences Corp.	2.7
Thermo Fisher Scientific Inc.	2.6
Beam Therapeutics Inc.	2.6
Genscript Biotech Corp.	2.5
Lonza Group AG, Registered	2.5
Legend Biotech Corp., ADR	2.5
Eli Lilly and Co.	2.5
Pfizer Inc.	2.4
10X Genomics Inc., Class A	2.4
CRISPR Therapeutics AG	2.4
QIAGEN NV	2.4
Samsung Biologics Co., Ltd.	2.4
Intellia Therapeutics Inc.	2.2
Biogen Inc.	2.2
Gilead Sciences Inc.	2.1
Bio-Techne Corp.	2.1
Natera Inc.	2.1
Twist Bioscience Corp.	2.1
Regeneron Pharmaceuticals Inc.	2.1
Total Net Assets (in \$000's)	\$6,133

The summary of investment portfolio may change due to ongoing portfolio transactions of the Fund and updates are available on a quarterly basis.

The prospectus and other information about the fund are available on the internet at www.ci.com.

